Venoms (10 μg) of B. arietans, E. p. leakeyi, N. nigricollis, N. pallida, N. haje and D. polylepis were separated by reduced SDS-PAGE and visualised by coomassie blue staining (Panel A). Venom proteins in identical gels were transferred to nitrocellulose blots and incubated with 1:5,000 dilutions of naïve Horse IgG (B), the ‘gold standard’ SAIMR polyvalent (C) and SAIMR ECHIS CARINATUS (D) antivenoms, and the ‘test’ Sanofi Pasteur (E), VINS (F), INOSAN (G) and Premium Serums & Vaccines (H) antivenoms. The antivenoms were not standardised to 5 mg/ml as in the ELISA assays.
In addition, the underlying data were not included with the original published article, and are provided here in S1 Table.
The authors apologize for the error in the published article.
- 1. Harrison RA, Oluoch GO, Ainsworth S, Alsolaiss J, Bolton F, Arias A-S, et al. (2017) Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa. PLoS Negl Trop Dis 11(10): e0005969. https://doi.org/10.1371/journal.pntd.0005969 pmid:29045429
Citation: Harrison RA, Oluoch GO, Ainsworth S, Alsolaiss J, Bolton F, Arias A-S, et al. (2020) Correction: Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa. PLoS Negl Trop Dis 14(8): e0008698. https://doi.org/10.1371/journal.pntd.0008698
Published: August 31, 2020
Copyright: © 2020 Harrison et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.